Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ7,17
KB-0,47
PKN68,9969,081,22
Msft2,32
Nokia4,3014,476-0,07
IBM2,46
Mercedes-Benz Group AG53,2153,231,58
PFE1,13
02.05.2025 23:31:57
Indexy online
AD Index online
select
AD Index online
 

  • 02.05.2025 22:00:00
Neogen Corp (NEOG.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
5,75 11,65 0,60 16 428 755
After-hours02.05.2025 23:20:00
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
5,75 - - 11,65 0,60
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 02.05.2025
Popis společnosti
Obecné informace
Název společnostiNeogen Corp
TickerNEOG
Kmenové akcie:Ordinary Shares
RICNEOG.O
ISIN-
Poslední známé roční výsledky31.05.2024
Poslední známé čtvrtletní výsledky28.02.2025
Počet zaměstnanců k 31.05.2024 2 917
Akcie v oběhu k 28.02.2025 217 038 267
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice620 Lesher Pl
MěstoLANSING
PSČ48912-1509
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon15 173 729 200
Fax15173722006

Business Summary: Neogen Corporation is engaged in developing, manufacturing and marketing a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. Its Food Safety segment consists primarily of diagnostic test kits and complementary products sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues and general sanitation concerns. The Company’s Animal Safety segment is engaged in the development, manufacture, marketing, and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services for the worldwide animal safety market.
Financial Summary: BRIEF: For the nine months ended 28 February 2025, Neogen Corp revenues decreased 3% to $669.2M. Net loss increased from $4M to $479.8M. Revenues reflect Food Safety segment decrease of 2% to $476.3M, Animal Safety segment decrease of 3% to $192.9M, Domestic segment decrease of 4% to $333.5M, International segment decrease of 1% to $335.7M. Higher net loss reflects Food Safety segment loss totaling $399.6M vs. income of $62.5M.
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Medical Equipment, Supplies & Distribution (NEC)
RBSS2004Medical Equipment, Supplies & Distribution
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSPesticide and Other Agricultural Chemical Manufacturing
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Electromedical Apparatus Mfg
NAICS2007Pesticide and Other Agricultural Chemical Manufacturing
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Pesticide and Other Agricultural Chemical Manufacturing
SICDiagnostic Substances
SICDiagnostic Substances
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICElectromedical Equipment
SICAgricultural Chemicals, Nec



  • Poslední aktualizace: 02.05.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorJohn Adent5617.07.2017
Chief Financial Officer, Chief Operating OfficerDavid Naemura5501.01.202502.01.2023
Chief Legal & Compliance OfficerAmy Rocklin52